Abstract
Obesity is considered a worldwide epidemic. Weight reduction by means of lifestyle changes is difficult to achieve, and pharmacotherapy is frequently needed. Although all currently approved anti-obesity agents have proven to be effective to achieve some degree of weight reduction and improve cardiometabolic risk factors, different compounds differ in their mechanism of action and safety profile. However, it is still difficult to achieve and maintain therapeutic objectives along time. The aim of the present article is to summarize the main characteristics of available anti-obesity agents and to explore novel agents that may provide significant clinical benefits in the future.
Keywords: Anti-obesity agents, obesity, pharmacotherapy, sibutramine, orlistat, rimonabant
Current Clinical Pharmacology
Title: Recent Advances in Obesity Pharmacotherapy
Volume: 4 Issue: 1
Author(s): Marcos A. Mayer, Christian Hocht, Ana Puyo and Carlos A. Taira
Affiliation:
Keywords: Anti-obesity agents, obesity, pharmacotherapy, sibutramine, orlistat, rimonabant
Abstract: Obesity is considered a worldwide epidemic. Weight reduction by means of lifestyle changes is difficult to achieve, and pharmacotherapy is frequently needed. Although all currently approved anti-obesity agents have proven to be effective to achieve some degree of weight reduction and improve cardiometabolic risk factors, different compounds differ in their mechanism of action and safety profile. However, it is still difficult to achieve and maintain therapeutic objectives along time. The aim of the present article is to summarize the main characteristics of available anti-obesity agents and to explore novel agents that may provide significant clinical benefits in the future.
Export Options
About this article
Cite this article as:
Mayer A. Marcos, Hocht Christian, Puyo Ana and Taira A. Carlos, Recent Advances in Obesity Pharmacotherapy, Current Clinical Pharmacology 2009; 4 (1) . https://dx.doi.org/10.2174/157488409787236128
DOI https://dx.doi.org/10.2174/157488409787236128 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Stem Cells for Ocular Tissue Engineering and Regeneration
Current Topics in Medicinal Chemistry Stem Cells in Pharmaceutical Biotechnology
Current Pharmaceutical Biotechnology D-amino Acids as Novel Blood-based Biomarkers
Current Medicinal Chemistry Role of Fibroblast Growth Factor Receptors in Astrocytic Stem Cells
Current Signal Transduction Therapy Cell Culture Models of Oxidative Stress and Injury in the Central Nervous System
Current Neurovascular Research Thiophene Ring-opening Reactions III: One-Pot Synthesis and Antitumor Activity of 1,3,4-Thiadiazoline–Benzothiazolo[3,2-<i>b</i>]pyridazine Hybrids†
Current Organic Synthesis Neuroprotection for Amyotrophic Lateral Sclerosis: Role of Stem Cells, Growth Factors, and Gene Therapy
Central Nervous System Agents in Medicinal Chemistry Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease
Current Topics in Medicinal Chemistry The Quest for Novel Biomarkers in Early Diagnosis of Diabetic Neuropathy
Current Proteomics Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy
Current Pharmaceutical Design Insights Into Effects of Ellagic Acid on the Nervous System: A Mini Review
Current Pharmaceutical Design Copy Number Variants in Neurological Disorder
Current Genomics Neurobiology of Depression and Novel Antidepressant Drug Targets
Current Pharmaceutical Design Glycogen Synthase Kinase-3: A Potential Target for Drug Discovery in the Treatment of Neurodegenerative Disorders
Current Enzyme Inhibition Proteasome Inhibition: A Promising Strategy for Treating Cancer, but What About Neurotoxicity?
Current Medicinal Chemistry Neuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules
Current Neuropharmacology Role of Dietary Antioxidants in Neurodegenerative Diseases: Where are We Standing?
Current Pharmaceutical Design Trends in Mitochondrial Therapeutics for Neurological Disease
Current Medicinal Chemistry Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases
Current Stem Cell Research & Therapy Neurokinin Peptides and Neurokinin Receptors as Potential Therapeutic Intervention Targets of Basal Ganglia in the Prevention and Treatment of Parkinsons Disease
Current Drug Targets